Module 2 Zanidatamab Flashcards
1
Q
Overall up to _____% BTC’s are HER 2+
A
30% (19.1%-31.3%)
2
Q
Of all the BTC subtypes HER2+ is most common among_____
A
GBC
3
Q
HER2+ % in eCCA _______
A
17.4 to 18.5%
4
Q
HER2+ in iCCA ________
A
3.7 to 4.8%
5
Q
Both _____ and _____ have been used in zanidatamab trials to evaluate HER2 positivity
A
FISH and CISH
6
Q
NGS measures (3)_______________
A
HER2 Gene Activating, Amplification, Alteration
7
Q
NGS is increasingly being used to detect HER2 ____________ in their BTC patients
A
Alterations
8
Q
MSI-H can be detected by ________ and ________
A
IHC and NGS
9
Q
In some cases HER2 gene amplification leads to _____________
A
HER2 Overexpression
